News

Overviews of all the latest meetings held by IGDRP are available here. For a list of recent documents published by IGDRP, see the Documents page.

Regulatory Collaboration - IGDRP generic drug product regulatory gap analysis

  • by IGDRP - 29 November 2016 - 4:20pm
News

The Brazilian Health Regulatory Agency (ANVISA) led a regulatory gap analysis survey under the auspices of IGDRP to identify regulatory similarities amongst the IGDRP members, and gaps that may create challenges for work-sharing and collaboration. The survey of the World Health Organization’s (WHO) Prequalification Team, the European Union, and 11 Regulatory Authorities covered the definition of a generic drug product and various regulatory and registration requirements for generic drugs, such as: 

Read More

Gap Analysis on ASMF/DMF frameworks and procedures

News

- J Pharm Pharm Sci. 2016 Apr-Jun; 19(2):290-300

By Pharmaceuticals and Medical Devices Agency(PMDA), Japan– 5  August  2016

The PMDA, on behalf of the IGDRP, investigated and have published a Gap Analysis on the ASMF/DMF frameworks and procedures of IGDRP members.  This paper has been published in the Journal of Pharmacy and Pharmaceutical Science entitled: Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence.

Read More

Common ASMF/DMF Submission Form (version 1.3, finalised March 2016)

News

The ability of IGDRP members to identify common ASMF/DMFs is a key focus of the IGDRP ASMF/DMF Working Group. Such identification would be facilitated if a common set of ASMF/DMF characteristics can be compared. Since key ASMF/DMF information is typically recorded by IGDRP members at the time of submission, ASMF/DMF Working Group members have worked to provide guidance on the type of information that should be recorded as part of an ASMF/DMF submission.

The resulting guidance is captured in the model Common ASMF/DMF Submission form.

Read More

ASMF/DMF Lexicon of Quality Terms (version 1.2, finalised May 2015)

News

IGDRP ASMF/DMF Working Group members come from a variety of Regulatory Authorities (RA’s) from around the world; each with their own regulatory terminology.

To ensure a common understanding among members, a Lexicon of Quality Terms has been developed for use by members and for use in documents produced by the IGDRP ASMF/DMF Working group. Since this may also be of benefit to the broader regulatory community, the decision was made to publish these terms and the result is the ASMF/DMF Lexicon of Quality Terms.

Read More

2nd International Generic Drug Regulators Programme (IGDRP) – Active Substance Master File (ASMF)/Drug Master File (DMF) Working Group - Public statement

News

With a view to improving international cooperation and work-sharing in the assessment of ASMF/DMF for generic drugs, the members of the ASMF/DMF Working Group held a face to face meeting as part of the 2nd meeting of the International Generic Drug Regulators Programme (IGDRP) in Seoul, South Korea from 2-5 November 2015.

Read More

The 1st International Generic Drug Regulators Programme (IGDRP) - Biowaivers Working Group - Public statement

News

The IGDRP Biowaivers working group was formed in May 2013 with the objective of establishing a common set of conditions for the granting of biowaivers as well as the expansion of the application of waivers. From the outset, this working group was provided with a scope and workplan to progress work on the use of Biopharmaceutical Classification System (BCS)-based biowaivers, biowaiver for additional or non-biostudy strengths of a solid dosage form product line, and biowaivers for certain dosage forms, e.g. solutions for parenteral, oral or local use .

Read More